loading
Lineage Cell Therapeutics Inc stock is traded at $0.9609, with a volume of 1.46M. It is down -2.94% in the last 24 hours and up +5.00% over the past month. Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
See More
Previous Close:
$0.99
Open:
$1
24h Volume:
1.46M
Relative Volume:
0.67
Market Cap:
$219.43M
Revenue:
$8.95M
Net Income/Loss:
$-21.49M
P/E Ratio:
-8.0075
EPS:
-0.12
Net Cash Flow:
$-29.24M
1W Performance:
-6.71%
1M Performance:
+5.00%
6M Performance:
+63.59%
1Y Performance:
-4.86%
1-Day Range:
Value
$0.9535
$1.01
1-Week Range:
Value
$0.9535
$1.12
52-Week Range:
Value
$0.3651
$1.15

Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile

Name
Name
Lineage Cell Therapeutics Inc
Name
Phone
510-871-4188
Name
Address
2173 Salk Avenue, Suite 200, Carlsbad, CA
Name
Employee
76
Name
Twitter
@LineageCell
Name
Next Earnings Date
2025-03-10
Name
Latest SEC Filings
Name
LCTX's Discussions on Twitter

Compare LCTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
LCTX
Lineage Cell Therapeutics Inc
0.9609 235.21M 8.95M -21.49M -29.24M -0.12
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.81 120.40B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
542.52 61.30B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.53 41.06B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
564.59 34.29B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.55 27.09B 3.81B -644.79M -669.77M -6.24

Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-20-24 Initiated Craig Hallum Buy
Nov-02-22 Initiated Robert W. Baird Outperform
Jun-14-22 Initiated B. Riley Securities Buy
Aug-19-21 Initiated Noble Capital Markets Outperform
Mar-31-21 Initiated Cantor Fitzgerald Overweight

Lineage Cell Therapeutics Inc Stock (LCTX) Latest News

pulisher
Jul 18, 2025

What analysts say about Lineage Cell Therapeutics Inc. stockOutstanding stock performance - Jammu Links News

Jul 18, 2025
pulisher
Jul 18, 2025

Lineage Cell Therapeutics Inc. Stock Analysis and ForecastHigh-yield capital appreciation - Jammu Links News

Jul 18, 2025
pulisher
Jul 18, 2025

What drives Lineage Cell Therapeutics Inc. stock priceFree Predictions - Jammu Links News

Jul 18, 2025
pulisher
Jul 18, 2025

Is Lineage Cell Therapeutics Inc. a good long term investmentBreakthrough investment results - Jammu Links News

Jul 18, 2025
pulisher
Jul 16, 2025

Stem Cell Therapy Market Attracts Investment in Neuro, Onco & - openPR.com

Jul 16, 2025
pulisher
Jul 15, 2025

What makes Lineage Cell Therapeutics Inc. stock price move sharplyFree Stock Market Practical Discussion Forums - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Lineage Cell Therapeutics Inc. stock attracts strong analyst attentionConsistent High Return Strategy - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Lineage Cell Therapeutics Inc. stock performs during market volatilityFree Stock Index Interpretation - Newser

Jul 15, 2025
pulisher
Jul 11, 2025

Cell Therapy Manufacturing Market Exclusive Report with - openPR.com

Jul 11, 2025
pulisher
Jul 03, 2025

Cell Therapy Manufacturing Market In-depth Insights, Business - openPR.com

Jul 03, 2025
pulisher
Jul 02, 2025

Lineage Cell Therapeutics shareholders approve board slate and equity plan amendment - Investing.com

Jul 02, 2025
pulisher
Jul 02, 2025

Lineage Cell Therapeutics unveils promising Phase I/IIa OpRegen results at CTS 2025 - Yahoo Finance

Jul 02, 2025
pulisher
Jun 23, 2025

Lineage Cell stock holds steady as Roche presents positive 3-year data By Investing.com - Investing.com South Africa

Jun 23, 2025
pulisher
Jun 13, 2025

Two Sigma Investments LP Buys New Shares in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World

Jun 13, 2025
pulisher
Jun 11, 2025

Rising Demand in Allogeneic Stem Cells Market USD 2.0Bn By 2031 - openPR.com

Jun 11, 2025
pulisher
Jun 11, 2025

Squarepoint Ops LLC Takes $46,000 Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Cell Therapy Manufacturing Market Exclusive Report with Detailed Study Analysis | WuXi AppTec, Healios Ltd. - newstrail.com

Jun 10, 2025
pulisher
Jun 09, 2025

Lineage Cell Therapeutics appoints new auditor - Investing.com Australia

Jun 09, 2025
pulisher
Jun 09, 2025

Two Sigma Advisers LP Has $44,000 Holdings in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World

Jun 09, 2025
pulisher
Jun 08, 2025

Jane Street Group LLC Buys 142,965 Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World

Jun 08, 2025
pulisher
Jun 05, 2025

Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium - BioSpace

Jun 05, 2025
pulisher
Jun 04, 2025

Deutsche Bank AG Has $87,000 Stock Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World

Jun 04, 2025
pulisher
May 27, 2025

Future of Personalized Treatment: Stem Cell Therapy Market - openPR.com

May 27, 2025
pulisher
May 26, 2025

B. Riley Predicts Lineage Cell Therapeutics FY2029 Earnings - Defense World

May 26, 2025
pulisher
May 21, 2025

Transcript : Lineage Cell Therapeutics, Inc. Presents at H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025, May-20-2025 02 - marketscreener.com

May 21, 2025
pulisher
May 20, 2025

Spinal cord injury Pipeline 2025: Groundbreaking Clinical - openPR.com

May 20, 2025
pulisher
May 19, 2025

Cell Therapy Manufacturing Market Is Booming Worldwide | WuXi - openPR.com

May 19, 2025
pulisher
May 17, 2025

Lineage Cell Therapeutics Q2 EPS Lowered by HC Wainwright - Defense World

May 17, 2025
pulisher
May 16, 2025

Lineage Cell Therapeutics outlines manufacturing milestone and anticipates OpRegen 36-month data update while advancing OPC1 clinical plans - MSN

May 16, 2025
pulisher
May 16, 2025

Comerica Bank Boosts Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World

May 16, 2025
pulisher
May 15, 2025

Lineage Cell Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks

May 15, 2025
pulisher
May 15, 2025

Barclays PLC Acquires 22,769 Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World

May 15, 2025
pulisher
May 14, 2025

Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Inve - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Lineage Cell Therapeutics Q1 2025 Earnings: EPS Beats Estimates at -$0.02, Revenue Misses at $1.5 Million - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q1 2025 Earnings Call Transcript - Insider Monkey

May 14, 2025
pulisher
May 14, 2025

Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC - Business Wire

May 14, 2025
pulisher
May 14, 2025

Wells Fargo & Company MN Increases Stake in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World

May 14, 2025
pulisher
May 14, 2025

Lineage Cell Therapeutics Inc (LCTX) Q1 2025 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance

May 14, 2025
pulisher
May 14, 2025

Lineage Cell Therapeutics Reports Q1 2025 Financials - TipRanks

May 14, 2025
pulisher
May 13, 2025

Lineage Cell: Q1 Earnings Snapshot - Huron Daily Tribune

May 13, 2025
pulisher
May 13, 2025

Lineage Cell Therapeutics earnings beat, revenue fell short of estimates By Investing.com - Investing.com Nigeria

May 13, 2025

Lineage Cell Therapeutics Inc Stock (LCTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$21.88
price down icon 0.59%
$35.59
price up icon 0.34%
$102.56
price down icon 1.55%
$26.20
price down icon 5.18%
$110.02
price down icon 0.92%
biotechnology ONC
$294.55
price up icon 1.45%
Cap:     |  Volume (24h):